share_log

Piper Sandler Maintains Overweight on Cue Biopharma, Raises Price Target to $8

Benzinga ·  Nov 6, 2023 10:40

Piper Sandler analyst Edward Tenthoff maintains Cue Biopharma (NASDAQ:CUE) with a Overweight and raises the price target from $7 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment